Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report)’s share price traded up 10.8% during trading on Wednesday. The stock traded as high as $2.95 and last traded at $3.0130. 3,952,764 shares changed hands during trading, a decline of 80% from the average session volume of 19,659,813 shares. The stock had previously closed at $2.72.
Analyst Ratings Changes
A number of analysts have recently commented on RXRX shares. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Monday, October 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, October 15th. JPMorgan Chase & Co. dropped their price target on Recursion Pharmaceuticals from $10.00 to $7.00 and set an “overweight” rating on the stock in a research note on Monday. Wall Street Zen raised shares of Recursion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Finally, Morgan Stanley dropped their target price on Recursion Pharmaceuticals from $5.90 to $5.60 and set an “equal weight” rating on the stock in a report on Wednesday. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $7.52.
Read Our Latest Stock Analysis on RXRX
Recursion Pharmaceuticals Stock Performance
The firm has a market cap of $1.69 billion, a PE ratio of -3.02 and a beta of 1.15. The firm’s 50 day moving average price is $3.73 and its two-hundred day moving average price is $3.46.
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported ($0.22) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.22). The company had revenue of $18.55 million during the quarter, compared to analysts’ expectations of $14.81 million. Recursion Pharmaceuticals had a negative return on equity of 47.85% and a negative net margin of 697.15%. During the same quarter in the previous year, the business earned ($0.36) earnings per share. On average, analysts forecast that Recursion Pharmaceuticals, Inc. will post -0.89 earnings per share for the current year.
Insider Buying and Selling
In related news, CEO Najat Khan sold 22,408 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $3.52, for a total transaction of $78,876.16. Following the completion of the sale, the chief executive officer directly owned 2,072,890 shares of the company’s stock, valued at $7,296,572.80. This represents a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $3.88, for a total transaction of $155,200.00. Following the completion of the sale, the director directly owned 6,068,287 shares of the company’s stock, valued at approximately $23,544,953.56. The trade was a 0.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 167,408 shares of company stock valued at $701,276 over the last 90 days. 6.65% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Recursion Pharmaceuticals
Several institutional investors and hedge funds have recently added to or reduced their stakes in RXRX. Renaissance Technologies LLC bought a new stake in Recursion Pharmaceuticals in the 1st quarter valued at about $7,370,000. Bank of New York Mellon Corp raised its stake in shares of Recursion Pharmaceuticals by 29.3% in the first quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company’s stock worth $4,490,000 after purchasing an additional 331,048 shares during the last quarter. Bank of America Corp DE grew its holdings in Recursion Pharmaceuticals by 18.2% during the first quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock valued at $7,665,000 after purchasing an additional 384,486 shares during the period. First Trust Advisors LP increased its holdings in Recursion Pharmaceuticals by 15.2% in the 1st quarter. First Trust Advisors LP now owns 2,610,726 shares of the company’s stock valued at $8,015,000 after acquiring an additional 344,035 shares during the last quarter. Finally, California State Teachers Retirement System raised its position in Recursion Pharmaceuticals by 64.0% in the 1st quarter. California State Teachers Retirement System now owns 574,637 shares of the company’s stock worth $1,764,000 after purchasing an additional 224,332 shares during the period. 89.06% of the stock is currently owned by institutional investors.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc. is a biotechnology company that uses automation, large-scale biological and chemical data, and machine learning to discover and develop medicines. Its platform, known as Recursion OS, is designed to identify relationships between biological processes and potential treatments. The company develops drug candidates for areas including rare diseases and oncology, and it also works with pharmaceutical partners on drug discovery and development. Its research combines laboratory experiments with computational analysis to evaluate potential therapeutic targets and compounds.
See Also
- Five stocks we like better than Recursion Pharmaceuticals
- Tesla and SpaceX May Form a $3.4 Trillion Giant, But Who Really Benefits?
- 2 Utility Stocks May Offer Relief From AI Volatility, But Rates Are the Real Story
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
